Kala Pharmaceuticals has been granted a patent for a method of treating ocular conditions using a fibronectin composition derived from mesenchymal stem cells. The composition excludes certain components to ensure efficacy. GlobalData’s report on Kala Pharmaceuticals gives a 360-degree view of the company including its patenting strategy. Buy the report here.

Smarter leaders trust GlobalData


Data Insights Kala Pharmaceuticals Inc - Company Profile

Buy the Report

Data Insights

The gold standard of business intelligence.

Find out more

According to GlobalData’s company profile on Kala Pharmaceuticals, Cancer treatment biomarkers was a key innovation area identified from patents. Kala Pharmaceuticals's grant share as of April 2024 was 43%. Grant share is based on the ratio of number of grants to total number of patents.

Ocular treatment method using msc-derived fibronectin composition

Source: United States Patent and Trademark Office (USPTO). Credit: Kala Pharmaceuticals Inc

A recently granted patent (Publication Number: US11919942B2) discloses a method for treating ocular conditions using a composition containing fibronectin (FN), specifically mesenchymal stem cell (MSC)-derived FN. The method involves administering the composition, which excludes various components such as xenobiotic components, peptides, and biomolecules less than 3 kDa, to a subject in need of treatment. The FN can be MSC-secreted or cellular FN, with the latter being non-covalently attached to growth factors like Extra Domain A+ (EDA+) and Extra Domain B+ (EDB+). The composition may also include growth factors such as fibroblast growth factors (FGFs), platelet-derived growth factor (PDGF), and vascular endothelial growth factor (VEGF) to aid in the treatment process.

Furthermore, the patent outlines specific concentrations of FN and other components in the composition, along with the inclusion of tonicity modifying agents like NaCl and mannitol. The method can be administered through topical application or subconjunctival injection and is targeted towards various ocular conditions such as ocular wounds, damaged corneal surfaces, and dry eye disease. Importantly, the composition excludes certain substances like insulin and hydrocortisone, as well as animal serum and non-exosome debris. This innovative method offers a promising approach to effectively treating a range of ocular conditions by utilizing MSC-derived FN and carefully curated components to enhance therapeutic outcomes while minimizing potential side effects.

To know more about GlobalData’s detailed insights on Kala Pharmaceuticals, buy the report here.

Data Insights


The gold standard of business intelligence.

Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.


GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData Patent Analytics tracks bibliographic data, legal events data, point in time patent ownerships, and backward and forward citations from global patenting offices. Textual analysis and official patent classifications are used to group patents into key thematic areas and link them to specific companies